Prevalence of T cell receptor ζ chain deficiency in systemic lupus erythematosus

被引:29
作者
Nambiar, MP
Mitchell, JP
Ceruti, RP
Malloy, MA
Tsokos, GC
机构
[1] Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD 20910 USA
[2] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA
[3] Walter Reed Army Med Ctr, Rheumatol Serv, Washington, DC 20307 USA
关键词
human T lymphocytes; lupus; signal transduction; SLEDAI; TCR zeta chain;
D O I
10.1191/0961203303lu281oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
T cells from patients with systemic lupus erythematosus (SLE) display antigen receptor-mediated signaling aberrations associated with defective T cell receptor (TCR) zeta chain expression. We determined the prevalence of TCR zeta chain deficiency in SLE from a large cohort of unselected racially diverse patients with different levels of clinical disease activity as determined by SLE Disease Activity Index (SLEDAI). Our data show that the occurrence of TCR zeta chain deficiency is 78% in SLE patients. There was no relationship between the deficiency of TCR zeta chain and the SLEDAI scores or therapy. TCR zeta chain deficiency was also not associated with age, race or gender and persisted over a 3 year follow-up period. Thus, there is a high prevalence of TCR zeta chain deficiency in SLE patients that is independent of disease activity, and persists over time indicating an important role for TCR zeta chain deficiency in SLE pathogenesis.
引用
收藏
页码:46 / 51
页数:6
相关论文
共 30 条
[1]  
Brundula V, 1999, ARTHRITIS RHEUM-US, V42, P1908, DOI 10.1002/1529-0131(199909)42:9<1908::AID-ANR17>3.0.CO
[2]  
2-7
[3]  
Enyedy EJ, 2001, ARTHRITIS RHEUM, V44, P1114, DOI 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO
[4]  
2-B
[5]   THE NON-LINEAR PHARMACOKINETICS OF PREDNISONE AND PREDNISOLONE .3. EXPERIMENTS USING THE RABBIT AS AN ANIMAL-MODEL [J].
FERRY, JJ ;
WAGNER, JG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1988, 9 (04) :363-376
[6]   RELATIVE AND ABSOLUTE BIOAVAILABILITY OF PREDNISONE AND PREDNISOLONE AFTER SEPARATE ORAL AND INTRAVENOUS DOSES [J].
FERRY, JJ ;
HORVATH, AM ;
BEKERSKY, I ;
HEATH, EC ;
RYAN, CF ;
COLBURN, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (01) :81-87
[7]   Genome screening in human systemic lupus erythematosus: Results from a second Minnesota cohort and combined analyses of 187 sib-pair families [J].
Gaffney, PM ;
Ortmann, WA ;
Selby, SA ;
Shark, KB ;
Ockenden, TC ;
Rohlf, KE ;
Walgrave, NL ;
Boyum, WP ;
Malmgren, ML ;
Miller, ME ;
Kearns, GM ;
Messner, RP ;
King, RA ;
Rich, SS ;
Behrens, TW .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (02) :547-556
[8]   A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families [J].
Gaffney, PM ;
Kearns, GM ;
Shark, KB ;
Ortmann, WA ;
Selby, SA ;
Malmgren, ML ;
Rohlf, KE ;
Ockenden, TC ;
Messner, RP ;
King, RA ;
Rich, SS ;
Behrens, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14875-14879
[9]  
Gastman BR, 1999, CANCER RES, V59, P1422
[10]   Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus [J].
Graham, RR ;
Langefeld, CD ;
Gaffney, PM ;
Ortmann, WA ;
Selby, SA ;
Baechler, EC ;
Shark, KB ;
Ockenden, TC ;
Rohlf, KE ;
Moser, KL ;
Brown, WM ;
Gabriel, SE ;
Messner, RP ;
King, RA ;
Horak, P ;
Elder, JT ;
Stuart, PE ;
Rich, SS ;
Behrens, TW .
ARTHRITIS RESEARCH, 2001, 3 (05) :299-305